Journal: Cancer discovery

Article Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers

doi: 10.1158/2159-8290.CD-20-0215

Figure Lengend Snippet: A) Isogenic breast epithelial cells MCF10A ectopically expressing either wild-type (WT) or mutant (S310F or L755S) HER2 or transduced with an empty vector (EV) control were incubated with T-DM1 conjugated to a red fluorescent pH-sensitive dye (pHrodo-T-DM1, 1 μg/mL) for 30 minutes at 4°C. Cells were then released at 37°C and Z-stack imaged every hour over 16 hours on a confocal microscope. Representative images of merged bright-field and Z-projected pHrodo signals depict intracellular red fluorescent dots, corresponding to T-DM1 reaching the endolysosomal compartments. Scale bar, 10 μm. B) Quantification of the experiment described in (A). Data are shown as number of normalized pHrodo dots per cell (Trafficking Index) over time. The error bars indicate SEM. Groups were compared to WT for each time point using 2-way ANOVA test. pValue *=<0.05, **=<0.01, ***=<0.001, ****=<0.0001 at the indicated time point, ns: non-significant. (n = 2 independent experiments, ≥80 cells analyzed in total per condition, per time point). C) Isogenic lung cancer cells NCI-H2030 ectopically expressing either wild-type (WT) or mutant (S310F or L755S) HER2 or transduced with an empty vector (EV) control were treated as in (A). Representative images of merged bright-field and Z-projected pHrodo signals depict intracellular red fluorescent dots, corresponding to T-DM1 reaching the endolysosomal compartments. Scale bar, 10 μm. D) Quantification of the experiment described in (D). Data are shown as number of normalized pHrodo dots per cell (Trafficking Index) over time. The error bars indicate SEM. Groups were compared to WT for each time point using 2-way ANOVA test. pValue *=<0.05, **=<0.01 at the indicated time point, ns: non-significant. (n = 2 independent experiments, ≥80 cells analyzed in total per condition, per time point). E) Western blot analysis of MCF10A isogenic models incubated with T-DM1 (10 μg/mL) or vehicle as control for 24 hours. Total and phospho-HER2, as well as and total phospho-tyrosine were assayed. Cleaved PARP was used to determine the apoptosis induction. Actin was included as loading control. F) Western blot analysis of NCI-H2030 isogenic models incubated with T-DM1 (10 μg/mL) or vehicle as control for 24 hours. Total and phospho-HER2, as well as and total phospho-tyrosine were assayed. Cleaved PARP was used to determine the apoptosis induction. Actin was included as loading control. G, H) 89Zr-Trastuzumab PET/CT scan representative images of ERBB2 amplified (G) and ERBB2 mutant (H) NSCLC patients (from a total of n=4 ERBB2 amplified and n=4 ERBB2 mutant NSCLC patients evaluated by 89Zr-Trastuzumab PET/CT scan). I) In vivo efficacy study of an ERBB2 YVMA mutant lung PDX treated with T-DM1 (15 mg/kg, i.v. once a week). Measurements show average tumor volumes +/− SEM, n=7 animals per group. J) In vivo efficacy study of a ERBB2 S310F mutant and amplified lung PDX treated with T-DM1 (15 mg/kg, i.v. once a week). Measurements show average tumor volumes +/− SEM, n=7 animals per group. Comparisons between the two groups for each time point were performed using 2-way ANOVA test, ****=<0.0001 pValue at the indicated time point.

Article Snippet: FISH was performed using FDA approved probe sets (PathVysion, Abbott and ERBB2 IQFISH pharmDx™, Dako).

Techniques: Expressing, Mutagenesis, Transduction, Plasmid Preparation, Incubation, Microscopy, Western Blot, Positron Emission Tomography-Computed Tomography, Amplification, In Vivo

Journal: Cancer discovery

Article Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers

doi: 10.1158/2159-8290.CD-20-0215

Figure Lengend Snippet: A) Calu-3 ERBB2-amplified NSCLC cells were incubated with pHrodo-T-DM1 (1 μg/mL) together with the pan-HER irreversible inhibitor neratinib (100 nM), the EGFR/HER2 reversible inhibitor lapatinib (100 nM), the inhibitor of endocytosis dynasore (100 μM) or DMSO control for 30 minutes at 4°C and then released at 37°C and Z-stack imaged every hour over 15 hours on a confocal microscope. Data are shown as number of normalized pHrodo dots per cell (Trafficking Index) over time. The error bars indicate SEM. Groups were compared to DMSO for each time point using 2-way ANOVA test. pValue ***=<0.001, ****=<0.0001 at the indicated time point, ns: non-significant. (n = 2 independent experiments, ≥80 cells analyzed in total per condition, per time point). B) LUAD-10 HER2-mutant L755P NSCLC cells were incubated with pHrodo-T-DM1 (10 μg/mL) together with the pan-HER irreversible inhibitor neratinib (10 nM), the pan-HER reversible inhibitor lapatinib (10 nM), the inhibitor of endocytosis dynasore (100 μM) or DMSO control for 30 minutes at 4°C and then released at 37°C and Z-stack imaged every hour over 15 hours on a confocal microscope. Data are shown as number of normalized pHrodo dots per cell (Trafficking Index) over time. The error bars indicate SEM. Groups were compared to DMSO for each time point using 2-way ANOVA test. pValue **=<0.01, ***=<0.001, ****=<0.0001 at the indicated time point, ns: non-significant. (n = 2 independent experiments, ≥80 cells analyzed in total per condition, per time point). C) Calu-3 cells were incubated with T-DM1 (10 μg/mL) or vehicle as control, together with the pan-HER irreversible inhibitors neratinib or afatinib (100 nM), the pan-HER reversible inhibitors lapatinib or tucatinib (100 nM) and HSP90 inhibitor (200 nM) in the presence of the proteasome inhibitor MG-132 (10 μM) for 6 hours at 37°C. HER2 immunoprecipitations (IPs) were performed using either T-DM1 itself or trastuzumab (added only to the protein lysates lacking T-DM1) as primary antibodies. IP or total lysate samples were evaluated by western blot. For the IP, ubiquitin and total HER2 were evaluated, showing a higher HER2 ubiquitination in the samples treated with neratinib, afatinib or HSP90 inhibitor. Ubiquitin and total HER2 were comparable among the total lysates, while phosphorylated HER2 on tyrosine 1248 (p-HER2 Y1248) demonstrated the efficacy of HER2 phosphorylation inhibition. Actin was included as loading control. D) LUAD-10 cells were incubated with T-DM1 (10 μg/mL) or IgG control, together with the irreversible HER2 inhibitors neratinib or afatinib (100 nM), the reversible HER2 inhibitors lapatinib or tucatinib (100 nM) and HSP90 inhibitor (100 nM) in the presence of the proteasome inhibitor MG-132 (10 μM) for 3 hours at 37°C. HER2 immunoprecipitations (IPs) were performed using T-DM1 itself (or IgG control) as primary antibody. IP or total lysate samples were analyzed by western blot. For the IP, ubiquitin and total HER2 were evaluated. Ubiquitin and total HER2 were comparable among the total lysates, while phosphorylated HER2 on tyrosine 1248 (p-HER2 Y1248) demonstrated the efficacy of HER2 phosphorylation inhibition. Actin was included as loading control. E) Isogenic lung cancer cells NCI-H2030 ectopically expressing either wild-type (WT) or mutant (S310F or L755S) HER2 or transduced with an empty vector (EV) control were treated as in (B). IP or total lysate samples were analyzed by western blot. For the IP, ubiquitin and total HER2 were evaluated. Ubiquitin and total HER2 were comparable among the total lysates, while phosphorylated HER2 on tyrosine 1248 (p-HER2 Y1248) demonstrated the efficacy of HER2 phosphorylation inhibition. Actin was included as loading control. F) In vivo efficacy study of the ERBB2 S310F mutant and amplified lung PDX shown in Figure 1e treated with T-DM1 (15 mg/kg, i.v. once a week), neratinib (20 mg/kg, p.o. every day, 5 days a week) and the combination. Measurements show average tumors volumes +/− SEM, n=7 animals per group. Comparisons between the two indicated groups for each time point were performed using 2-way ANOVA test, ****=<0.0001 pValue at the indicated time point. G) CT scan of ERBB2 amplified breast cancer patient who relapsed after T-DM1 single agent treatment and responded to T-DM1+neratinib combination. Arrows point to two different metastatic lesions during T-DM1 monotherapy and after the addition of neratinib.

Article Snippet: FISH was performed using FDA approved probe sets (PathVysion, Abbott and ERBB2 IQFISH pharmDx™, Dako).

Techniques: Amplification, Incubation, Microscopy, Mutagenesis, Western Blot, Inhibition, Expressing, Transduction, Plasmid Preparation, In Vivo, Computed Tomography

Journal: Cancer discovery

Article Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers

doi: 10.1158/2159-8290.CD-20-0215

Figure Lengend Snippet: A, B) Waterfall plots showing best overall response to T-DM1 treatment in 48 NSCLC patients, not including one patient who did not have RECIST or PERCIST measurable disease but was still evaluable for progression-free survival study. Colors indicate ERBB2 alteration status (A) or best response (B). Overall Response Rate (ORR) was 51% (25/49, 95% Confidence interval (CI): 36–66). Asterisks indicate responses by PERCIST, otherwise response was assessed by RECISTv1.1. C) Swimmer’s plot showing duration of treatment on T-DM1. Arrow indicates treatment is ongoing at the time of data cut off. Mean PFS: 5.6 months, median PFS: 5.0 months. Mean DOR: 4.2 months, median DOR: 4.4 months.

Article Snippet: FISH was performed using FDA approved probe sets (PathVysion, Abbott and ERBB2 IQFISH pharmDx™, Dako).

Techniques:

Journal: Cancer discovery

Article Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers

doi: 10.1158/2159-8290.CD-20-0215

Figure Lengend Snippet: A) In vivo efficacy study of the ERBB2 S310F mutant and amplified lung PDX shown in Figures 1E and ​and3D3D treated with T-DM1 (15 mg/kg, i.v. once a week) and T-DXd (10 mg/kg, i.v. once every 3 weeks). Measurements show average tumor volumes +/− SEM, n=7 animals per group. Comparisons between the two indicated groups for each time point were performed using 2-way ANOVA test, ****=<0.0001 pValue at the indicated time point. B) CT-scan of the ERBB2 S310F mutant and amplified lung cancer patient corresponding to the PDX shown in Figure 4c. Arrows point to a bone metastatic lesion at T-DM1 progression and after response to T-DXd. C) In vivo efficacy study of a ERBB2 YVMA mutant lung PDX treated with T-DM1 (15 mg/kg, i.v. once a week), neratinib (20 mg/kg, p.o. 5 days a week), T-DM1+neratinib and T-DXd (10 mg/kg, i.v. once every 3 weeks). Measurements show average tumor volumes +/− SEM, n=6 animals per group. Comparisons between the two indicated groups for each time point were performed using 2-way ANOVA test, ****=<0.0001 pValue at the indicated time point. D) Schematic showing the two strategies proposed in this work to enhance the efficacy of anti-HER2 ADC in lung cancer: increased internalization by pan-HER irreversible inhibitors through increased ubiquitination and consequent endocytosis of the receptor-ADC complex in both ERBB2 mutant or amplified tumors; switching anti-HER2 ADCs from T-DM1 to T-DXd.

Article Snippet: FISH was performed using FDA approved probe sets (PathVysion, Abbott and ERBB2 IQFISH pharmDx™, Dako).

Techniques: In Vivo, Mutagenesis, Amplification, Computed Tomography